Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The suspension is not therapeutically equivalent to ALDACTONE tablets. Its renal sentence gives a starting amount without a distinct frequency.
Before applying: Do not import a tablet alternate-day schedule. Resolve the frequency in the exact product and indication context.
Also check: Suspension non-equivalence and an incompletely specified renal starting instruction
Official source
CAROSPIR - official formulation and renal monitoring check
Product / population
CAROSPIR - official formulation and renal monitoring check; selected renal passages, not a complete prescribing monograph.
Renal measure
eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
Renal dosing, restrictions and evidence limits
Section 2.2 advises considering 10 mg (2 mL) for heart-failure initiation at eGFR 30-50 mL/min/1.73 m2. That renal sentence does not give a distinct administration frequency. CAROSPIR is not therapeutically equivalent to ALDACTONE. Check potassium within one week of starting or titrating, then regularly; closer monitoring may be needed with renal impairment or potassium-raising medicines. Monitor volume status and renal function. Do not silently convert the tablet regimen or invent a dialysis dose.
Source revision: Prescribing information revised September 2023. | Retrieved: 2026-09-09. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
formulation and source limit
Suspension non-equivalence and an incompletely specified renal starting instruction
The suspension is not therapeutically equivalent to ALDACTONE tablets. Its renal sentence gives a starting amount without a distinct frequency.
How to use this: Do not import a tablet alternate-day schedule. Resolve the frequency in the exact product and indication context.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source
CAROSPIR - official formulation and renal monitoring check
CAROSPIR - official formulation and renal monitoring check; selected renal passages, not a complete prescribing monograph.
Method: eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
DailyMed / CMP Pharma, Inc. · CAROSPIR - official formulation and renal monitoring check; selected renal passages, not a complete prescribing monograph.
Renal method: eGFR in mL/min/1.73 m2; preserve body-surface-area indexing. Source date: Prescribing information revised September 2023. Retrieved: 2026-09-09
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Section 2.2 advises considering 10 mg (2 mL) for heart-failure initiation at eGFR 30-50 mL/min/1.73 m2. That renal sentence does not give a distinct administration frequency. CAROSPIR is not therapeutically equivalent to ALDACTONE. Check potassium within one week of starting or titrating, then regularly; closer monitoring may be needed with renal impairment or potassium-raising medicines. Monitor volume status and renal function. Do not silently convert the tablet regimen or invent a dialysis dose.
RDM53-official-spironolactone-carospir-40ccdc8349-C1 · Source locator: Sections 2.1-2.2 and 5.1-5.2; strength 25 mg/5 mL; printed PI revision.
GlobalRPh-hosted RX List · CAROSPIR spironolactone oral suspension 25 mg/5 mL; adult heart-failure renal initiation context. Not ALDACTONE tablets.
Renal method: eGFR in mL/min/1.73 m2; preserve body-surface-area indexing. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-09
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For heart failure with eGFR 30-50 mL/min/1.73 m2, this suspension source says to consider a 10 mg (2 mL) starting amount because of hyperkalemia risk. CAROSPIR is not therapeutically equivalent to ALDACTONE; use the suspension instructions rather than a milligram-for-milligram tablet substitution. The renal sentence does not specify a separate frequency. Review the full heart-failure dosing context; no schedule below this studied/label-described range or dialysis dose is inferred.
RDM53-rxlist-spironolactone-carospir-66050bf2be-C1 · Source locator: Dosage: general considerations and treatment of heart failure.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.